Clinical Trial Update: An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [NA]

View source ↗

Summary

Open-label, multicenter expanded-access study of nilotinib (AMN-107) in adults with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: King Faisal Specialist Hospital & Research Center | Conditions: Leukemia, Myeloid, Chronic | NA | Status: COMPLETED